At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 17 enrolled
Drug / intervention
Ryanodex and Standard of Care +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
In Brief
A Phase 3 clinical trial evaluating Ryanodex and Standard of Care and Standard of Care for Exertional Heat Stroke. Completed, enrolled 17 participants across 4 sites.
Detailed Summary
A double-blind, parallel study of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) compared to current Standard of Care (SOC) for EHS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExertional Heat Stroke
CountriesSaudi Arabia
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartAug 2018
Primary CompletionAug 2019
TodayJul 2026
First PostedJul 26, 2018
Enrollment StartAug 19, 2018
Primary CompletionAug 14, 2019
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 7.9 years ago
Interventions
Ryanodex and Standard of Caredrug
Ryanodex to be administered as a rapid IV push
Standard of Careother
Body cooling measures and supportive measures